Loading...
Market
Will PTC Therapeutics' AADC gene therapy be approved in the EU by end of 2025?
4
Resolution / Starting Odds
Yes • 50%
No • 50%
European Medicines Agency announcements
Story
FDA Approves PTC Therapeutics' Gene Therapy for AADC Deficiency
Nov 13, 2024, 11:18 PM
The U.S. Food and Drug Administration (FDA) has approved PTC Therapeutics' gene therapy for Aromatic L-Amino Acid Decarboxylase (AADC) deficiency, a potentially fatal enzyme deficiency disorder. This therapy is administered directly in the brain, marking a significant advancement in the treatment of neurological conditions. The approval has positively impacted PTC Therapeutics' stock, which saw a 2% increase in aftermarket trading.
View original story
Similar markets
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
Yes • 50%
No • 50%
